preloader

Thanks to you, "BIG Time for Baby" is making progress.

Intro text: 

Thanks to you, "BIG Time for Baby" is making progress, with already 262 women enrolled and 32 healthy babies born.

The trial, launched in 2014, is steadily enrolling patients, giving hope to thousands of women wishing to have a baby after breast cancer.

POSITIVE, the official scientific name of the study, was developed for all young breast cancer patients who face the disease before having addressed their family planning wishes. Women with breast cancer may not have time to wait until after 5 to 10 years of treatment before considering pregnancy. The 'BIG Time for Baby' trial expects to provide an answer to the question of whether women can interrupt their endocrine treatment to try to have a baby, without increasing the risk of cancer recurrence. 

At the end of June 2018, a halfway milestone was reached: 262 of 500 patients enrolled in the study, in more than 15 countries. Today there are already more than 32 healthy babies born.

 SUPPORT THIS STUDY AND GIVE HOPE.

This trial provides a unique opportunity to gather definitive research data about the safety of interrupting therapy to attempt pregnancy after breast cancer, something that is currently lacking.
 

www.BIGtimeforbaby.org

 

Make breast cancer patients’ dream of having a baby come true

Thanks to you, "BIG Time for Baby" makes progress.

Intro text: 

The trial, launched in 2014, is steadily developing proof, giving hope to thousands of women wishing to have a baby after breast cancer.

POSITIVE, the official scientific name of the study, was launched for all young breast cancer patients who face the disease before having addressed their family planning. Women patients may not have time to wait for 5 to 10 years of treatment completion before considering pregnancy. The 'BIG Time for Baby' trial might provide a solution. It investigates endocrine therapy interruption, to enable conception for young women between 18 and 42 years of age with endocrine-responsive early breast cancer. They all received adjuvant endocrine therapy for 18 to 30 months and wish to attempt pregnancy.

At the end of June 2018, halfway a milestone was reached: 262 patients enrolled in the study, in more than 15 countries. Today there are already more than 32 healthy babies born.

This trial is a unique opportunity to gather definitive and prospective research data regarding the safety of pregnancy after breast cancer, something that is currently missing.

 

SUPPORT THIS STUDY AND GIVE HOPE.